Title : A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.

Pub. Date : 2013 Sep

PMID : 23726675






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Naloxegol (previously known as NKTR-118) is a peripherally acting mu-opioid receptor antagonist engineered using polymer conjugate technology in development as an oral, once-daily agent for the treatment of opioid-induced constipation (OIC). naloxegol natural killer cell triggering receptor Homo sapiens